Edit Symbol List
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Company Description (as filed with the SEC)
VIVUS is a biopharmaceutical company with two FDA-approved therapies, Qsymia and STENDRA. Our drug Qsymia (phentermine and topiramate extended-release) was approved by the FDA on July 17, 2012, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates a proprietary formulation combining low doses of active ingredients from two previously approved drugs, phentermine and topiramate. Although the exact mechanism of action is unknown, Qsymia is believed to suppress appetite and increase satiety, or the feeling of being full, the two main mechanisms that impact eating behavior. On September 17, 2012, we announced the U.S. ... More ...
|Annual EPS Est:||$-1.51|
|Quarterly EPS Est:||-0.31|